BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16647810)

  • 21. The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients.
    Bachmann HS; Otterbach F; Callies R; Nückel H; Bau M; Schmid KW; Siffert W; Kimmig R
    Clin Cancer Res; 2007 Oct; 13(19):5790-7. PubMed ID: 17908970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12.
    Floros KV; Thomadaki H; Lallas G; Katsaros N; Talieri M; Scorilas A
    Ann N Y Acad Sci; 2003 Dec; 1010():153-8. PubMed ID: 15033711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular profile of the BCL2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs.
    Thomadaki H; Scorilas A
    Connect Tissue Res; 2008; 49(3):261-4. PubMed ID: 18661356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin.
    Floros KV; Thomadaki H; Katsaros N; Talieri M; Scorilas A
    Biol Chem; 2004 Nov; 385(11):1099-103. PubMed ID: 15576332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
    Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
    Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positive BCL2L12 expression predicts favorable prognosis in patients with laryngeal squamous cell carcinoma.
    Giotakis AI; Lazaris AC; Kataki A; Kontos CK; Giotakis EI
    Cancer Biomark; 2019; 25(2):141-149. PubMed ID: 31104007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCL2L12: a multiply spliced gene with independent prognostic significance in breast cancer.
    Kladi-Skandali A; Sideris DC; Scorilas A
    Clin Chem Lab Med; 2018 Dec; 57(2):276-287. PubMed ID: 30325729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol.
    Korbakis D; Scorilas A
    Tumour Biol; 2012 Jun; 33(3):865-75. PubMed ID: 22238053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker.
    Papageorgiou SG; Kontos CK; Pappa V; Thomadaki H; Kontsioti F; Dervenoulas J; Papageorgiou E; Economopoulos T; Scorilas A
    Oncologist; 2011; 16(9):1280-91. PubMed ID: 21737576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCL2L12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma.
    Fendri A; Kontos CK; Khabir A; Mokdad-Gargouri R; Scorilas A
    Mol Med; 2011; 17(3-4):163-71. PubMed ID: 21152697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
    Rody A; Karn T; Ruckhäberle E; Müller V; Gehrmann M; Solbach C; Ahr A; Gätje R; Holtrich U; Kaufmann M
    Breast Cancer Res Treat; 2009 Feb; 113(3):457-66. PubMed ID: 18340528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
    J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. mRNA expression of the putative antimetastatic gene BRMS1 and of apoptosis-related genes in breast cancer.
    Schneider J; Gómez-Esquer F; Díaz-Gil G; Torrejón R; Pollán M
    Cancer Genomics Proteomics; 2011; 8(4):195-7. PubMed ID: 21737612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Effects of Treatment of Human Colorectal Cancer Cells with Natural and Classical Chemotherapeutic Drugs: Alterations in the Expression of Apoptosis-related BCL2 Family Members, Including BCL2L12.
    Kontos CK; Avgeris M; Vassilacopoulou D; Ardavanis A; Scorilas A
    Curr Pharm Biotechnol; 2018; 19(13):1064-1075. PubMed ID: 30417787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach.
    Tozlu S; Girault I; Vacher S; Vendrell J; Andrieu C; Spyratos F; Cohen P; Lidereau R; Bieche I
    Endocr Relat Cancer; 2006 Dec; 13(4):1109-20. PubMed ID: 17158757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Down-regulation of PHLDA1 gene expression is associated with breast cancer progression.
    Nagai MA; Fregnani JH; Netto MM; Brentani MM; Soares FA
    Breast Cancer Res Treat; 2007 Nov; 106(1):49-56. PubMed ID: 17211533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.
    Jansson AK; Gunnarsson C; Cohen M; Sivik T; Stål O
    Cancer Res; 2006 Dec; 66(23):11471-7. PubMed ID: 17145895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy.
    Jezierska A; Matysiak W; Motyl T
    Med Sci Monit; 2006 Aug; 12(8):BR263-73. PubMed ID: 16865058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.